Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Berlin
Clinical trial register · Germany

Clinical Trials in Berlin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5081 matching records held by the registry are in this view. Synced 13 Nov 2026, 03:18 UTC
5081
Studies in scope
all four open statuses
2880
Recruiting now
open to new participants
985
Lead sponsors
across recruiting studies
Top sites
Berlin 1591 Hamburg 896 Essen 767 Dresden 717 Heidelberg 626
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca118 Charite University, Berlin, Germany89 Janssen Research & Development, LLC49 Eli Lilly and Company47 Novartis Pharmaceuticals45 Hoffmann-La Roche40 Merck Sharp & Dohme LLC40 Sanofi32 Boehringer Ingelheim28 Pfizer28 Bristol-Myers Squibb25 Novo Nordisk A/S25 AbbVie24 Amgen19 GlaxoSmithKline18 Takeda16 Incyte Corporation16 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest14 Gilead Sciences13 Daiichi Sankyo13 Abbott Medical Devices12 Alexion Pharmaceuticals, Inc.11 argenx11 Universitätsklinikum Hamburg-Eppendorf10 Ipsen10 Show all 530
Site location
Berlin1591 Hamburg896 Essen767 Dresden717 Heidelberg626 Cologne619 Leipzig515 München513 Hanover488 Tübingen457 Bonn424 Düsseldorf409 Munich398 Freiburg im Breisgau392 Erlangen373 Frankfurt369 Münster359 Frankfurt am Main346 Ulm343 Mainz336 Würzburg299 Aachen267 Augsburg248 Kiel236 Lübeck225 Show all 642
All 642 locations
Target enrolment
to

Trials with a site in Berlin

1591 of 5081 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Not yet open
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
Berlin, Hanover, Münster, Cologne, Homburg, Leipzig, Kiel, Essen
2027-11-23
Not yet open
Liver Transplantation for Non-Resectable Colorectal Liver Metastases Without Local Treatment Options
NCT07811453Colorectal Neoplasms, Liver Neoplasms, Neoplasm Metastases, Colorectal Liver Metastases
Charite University, Berlin, Germany
Not applicable
260
Berlin
2027-04-01
Not yet open
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
92
Berlin, Cologne, Erlangen, Leipzig, München, Tübingen, Würzburg
2027-02-03
Not yet open
IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas
NCT07888647Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4
DrugsImiquimod·Temozolomide
German Cancer Research Center
Phase 2
216
Berlin, Bonn, Cologne, Dresden, Erlangen, Essen, Frankfurt, Heidelberg
2027-02-01
Not yet open
Boehringer Ingelheim
Phase 3
1,500
Aachen, Ahrensburg, Bamberg, Berlin, Bochum, Bonn, Cologne, Donaustauf
2027-01-11
Not yet open
Bayer
Phase 1
36
Heidelberg, Bonn, Erfurt, Berlin
2027-01-01
Not yet open
Stratification and Treatment in Early Psychosis Study -ASSIST
NCT07326124Treatment Resistant Psychosis, Psychosis
University of Oxford
Phase 3
250
Berlin, Cologne, Munich
2027-01
Not yet open
Boehringer Ingelheim
Phase 3
270
Bad Bramstedt, Berlin, Cologne, Erlangen, Freiburg im Breisgau, Halle, Jena, Kirchheim unter Teck
2026-12-14
Not yet open
Stratification and Treatment in Early Psychosis Study - PROMOTE
NCT07434973Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis, Clinical High Risk for Developing Psychosis
DrugCannabidiol
University of Oxford
Phase 3
586
Berlin, Cologne, Lübeck, München
2026-12-01
Not yet open
CD19-B Cell Depletion in PAIS-ME/CFS Patients
NCT07724834Post-acute Infectious Syndrome (PAIS), Post-COVID 19 Condition (PCC or Long COVID), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
DrugInebilizumab
Charite University, Berlin, Germany
Phase 2
38
Berlin
2026-12-01
Not yet open
Dalbavancin Therapy for Infective Endocarditis
NCT07699211Endocarditis Infective, Endocarditis, Bacterial
DrugDalbavancin administration
Stefan Hagel
Phase 3
184
Freiburg im Breisgau, Regensburg, Hamburg, Cologne, Leipzig, Berlin, Erfurt, Jena
2026-12
Not yet open
Eli Lilly and Company
Phase 3
3,000
Berlin, Bochum, Elsterwerda, Frankfurt, Lübeck, Mannheim, Offenbach, Oldenburg
2026-12
Not yet open
Eli Lilly and Company
Phase 3
2,115
Berlin, Bochum, Cologne, Essen, Gladbeck, Hamburg, Leipzig, Lübeck
2026-12
Not yet open
Global Antibiotics Research and Development Partnership
Phase 4
200
Berlin
2026-12
Not yet open
Validation Of anatomY-specific Aortic Valve Implantation Guided by Software Using EncantoR
NCT07696182Severe Native Calcific Aortic Stenosis, Symptomatic Heart Disease Due to Severe Native Calcific Aortic Stenosis
Abbott Medical Devices
Not applicable
300
Bad Nauheim, Bad Oeynhausen, Berlin, Dortmund, Dresden, Frankfurt, Hamburg, Kiel
2026-11-30
Not yet open
DETECTRA: Remote Monitoring to Detect Rheumatoid Arthritis Flares and Treatment Response
NCT07857993Rheumatic Disorder, Rheumatoid Arthritis (RA)
Centre Hospitalier Universitaire Vaudois
Not applicable
320
Berlin, Bochum
2026-11-30
Not yet open
Charite University, Berlin, Germany
Not applicable
60
Berlin
2026-11-15
Not yet open
Boehringer Ingelheim
Phase 2
70
Aachen, Berlin, Donaustauf, Solingen, Stralstund
2026-11-13
Not yet open
Novo Nordisk A/S
Phase 3
1,408
Berlin, Duisburg, Elsterwerda, Frankfurt, Hamburg, Münster, Oldenburg in Holstein
2026-11-11
Not yet open
Novo Nordisk A/S
Phase 3
450
Bad Mergentheim, Berlin, Ludwigshafen, Mainz, Münster, Pirna, Pohlheim
2026-11-10
Not yet open
Novo Nordisk A/S
Phase 3
1,200
Bad Oeynhausen, Berlin, Duisburg, Falkensee, Gladbeck, Hamburg, Köln-Dünnwald, Leipzig
2026-11-10
Not yet open
German Heart Institute
Observational
250
Berlin
2026-11-09
Recruiting
Boehringer Ingelheim
Phase 1
40
Berlin
2026-11-03
Not yet open
Microneedle-based ISF Sampling Technique
NCT07882225No Condition, Healthy Individuals
Ascilion AB
Not applicable
110
Berlin
2026-11
Recruiting
Thomas Ernst, Prof. Dr. med.
Phase 2
50
Aachen, Berlin, Chemnitz, Dresden, Hamburg, Hanover, Jena, Leipzig
2026-11
Not yet open
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
NCT07873931Systemic Lupus Erythematosus, Sjögren's Disease, Rheumatoid Arthritis, Idiopathic Inflammatory Myopathies
Bristol-Myers Squibb
Phase 1
60
Berlin, Erlangen, Magdeburg, Würzburg
2026-10-30
Recruiting
Surgical Treatment of Adjacent Segment Stenosis
NCT07661199Adjacent Segment Disease, Lumbar Spinal Stenosis
Charite University, Berlin, Germany
Not applicable
338
Berlin
2026-10-27
Recruiting
LIfestyle MEtabotype Study B (LIME-B)
NCT07888257Nutritional and Metabolic Diseases, Prediabetes, Type 2 Diabetes
German Institute of Human Nutrition
Not applicable
300
Berlin, Nuthetal
2026-10-26
Not yet open
Novo Nordisk A/S
Phase 3
8,500
Aachen, Bad Oeynhausen, Berlin, Dessau, Dresden, Elsterwerda, Essen, Frankfurt
2026-10-26
Recruiting
Assessment of Communication Interventions on Vaccination Knowledge and Acceptance
NCT07921121Vaccination Knowledge and Acceptance, Informed Vaccine-decision Making
Charite University, Berlin, Germany
Not applicable
1,524
Berlin
2026-10-23
Recruiting
Novo Nordisk A/S
Phase 3
84
Berlin, Bonn, Hanover, Leipzig, Regensburg
2026-10-16
Not yet open
Aristotle University Of Thessaloniki
Observational
50
München, Berlin
2026-10-15
Recruiting
Bristol-Myers Squibb
Phase 1/2
84
München, Berlin, Cologne, Herne, Sendenhorst
2026-10-06
Recruiting
Ad scientiam
Not applicable
100
Berlin, Bochum, München
2026-10-06
Recruiting
Hoffmann-La Roche
Phase 3
400
Berlin, Bielefeld, Essen, Esslingen am Neckar
2026-10-06
Recruiting
Stratification and Treatment in Early Psychosis Study - ENHANCE
NCT06778564Psychosis, First Episode Psychosis, Psychotic Disorders, Psychotic Episode
University of Oxford
Phase 3
250
Augsburg, Berlin, Cologne, Munich
2026-10-05
Not yet open
First-line Treatment in Locally Advanced or Metastastic Small Bowel Adenocarcinoma
NCT07844057Small-bowel Adenocarcinoma, Metastatic Disease, Chemotherapy Effect
Annika Kurreck
Phase 2
86
Augsburg, Bad Saarow, Berlin, Chemnitz, Frankfurt, Herne, Landshut, München
2026-10-01
Not yet open
Post-acute Infectious Syndrome - Aripiprazole Symptom Evaluation (PAIS-AriSE)
NCT07714213Post-acute Infectious Syndrome (PAIS), Post-COVID-19 Condition (PCC or Long COVID)
DrugAripiprazole
Christiana Franke
Phase 2
138
Berlin
2026-10-01
Not yet open
Charite University, Berlin, Germany
Phase 3
267
Berlin
2026-10-01
Not yet open
OM336 in Sensitized Transplant Candidates
NCT07789431Highly Sensitized Patients Awaiting Kidney Transplant
Medical University of Vienna
Phase 2
12
Berlin
2026-10-01
Recruiting
Ludwig-Maximilians - University of Munich
Phase 2
36
Munich, Berlin, Hamburg, Hanover
2026-10-01
Not yet open
AngioVac Aspiration Therapy Registry
NCT07769320Intracardiac Thrombus, Intracardiac Mass, Intravascular Thrombosis, Vegetation; Heart
Charite University, Berlin, Germany
Observational
1,000
Berlin
2026-10-01
Recruiting
Register for Medical Data, Functional Scales, and Care Outcomes in ALS, SMA, and Other Motor System Disorders
NCT07900672ALS (Amyotrophic Lateral Sclerosis), SMA - Spinal Muscular Atrophy, Spinal Cord Diseases, Central Nervous System Diseases
Ambulanzpartner Soziotechnologie APST GmbH
Observational
2,000
Berlin
2026-10-01
Not yet open
Daiichi Sankyo
Phase 3
103
Berlin, Hamburg, Mainz, Mannheim
2026-09-30
Not yet open
Centre Hospitalier Universitaire Vaudois
Not applicable
142
Berlin, Bochum
2026-09-28
Recruiting
Philogen S.p.A.
Phase 2
180
Augsburg, Berlin, Essen, Halle, Kiel, Tübingen
2026-09-28
Recruiting
Takeda
Observational
94
Cologne, Berlin
2026-09-24
Recruiting
AstraZeneca
Phase 3
750
Berlin, Dresden, Essen, Freiburg im Breisgau, Hamburg, Leipzig, München, Oldenburg
2026-09-24
Recruiting
University Hospital Tuebingen
Phase 2
84
Heidelberg, Tübingen, Berlin, Essen
2026-09-24
Recruiting
Novartis Pharmaceuticals
Phase 2
180
Stuttgart, Kaiserslautern, Berlin, Mannheim, Pirna
2026-09-18
Recruiting
Boehringer Ingelheim
Phase 3
466
Berlin, Bonn, Essen, Hanover, Heidelberg, München, Stuttgart
2026-09-17
Recruiting
Debiopharm International SA
Phase 1
60
Berlin
2026-09-16
Recruiting
AstraZeneca
Phase 3
950
Berlin, Bonn, Düsseldorf, Hanover, Wiesbaden
2026-09-16
Recruiting
AstraZeneca
Phase 3
1,330
Bergisch Gladbach, Berlin, Bonn, Cologne, Dresden, Duisburg, Essen, Frankfurt am Main
2026-09-15
Recruiting
Vividion Therapeutics, Inc.
Phase 2
140
Ulm, Schweinfurt, Hamburg, Frankfurt am Main, Oldenburg, Essen, Berlin
2026-09-11
Recruiting
AstraZeneca
Phase 3
200
Berlin, Essen, Frankfurt, Freiburg im Breisgau, Hanover, Kaiserslautern, Leipzig, Munich
2026-09-10
Recruiting
Boehringer Ingelheim
Phase 1
20
Berlin
2026-09-10
Recruiting
RyCarma Therapeutics, Inc.
Phase 2
28
Ulm, Berlin
2026-09-09
Recruiting
Incyte Corporation
Phase 3
426
Aachen, Berlin, Dresden, Freiburg im Breisgau, Halle, Hamburg, Hanover, Homburg
2026-09-08
Recruiting
Novo Nordisk A/S
Phase 1
320
Berlin
2026-09-07
Not yet open
Novo Nordisk A/S
Phase 1
54
Berlin
2026-09-04
By invitation
Max Planck Social Neuroscience Lab
Not applicable
666
Berlin
2026-09-02
Recruiting
Charite University, Berlin, Germany
Phase 3
750
Berlin
2026-09-01
Recruiting
Massachusetts General Hospital
Phase 4
540
Berlin
2026-09-01
Recruiting
AstraZeneca
Phase 3
2,800
Aachen, Bad Nenndorf, Berlin, Bonn, Brandenburg an der Havel, Braunschweig, Cloppenburg, Essen
2026-09-01
Recruiting
Charite University, Berlin, Germany
Observational
191
Berlin
2026-09-01
Recruiting
L19IL2/TNF in Patients With Basal Cell Carcinoma
NCT07227870Locally Advanced Basal Cell Carcinoma
DrugDaromun
Philogen S.p.A.
Phase 2
92
Augsburg, Berlin, Essen, Halle, Heidelberg, Kiel, Tübingen
2026-09
Recruiting
L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma
NCT07228442Locally Advanced Cutaneous Squamous Cell Carcinoma
DrugDaromun
Philogen S.p.A.
Phase 2
92
Augsburg, Berlin, Essen, Halle, Heidelberg, Kiel, Tübingen
2026-09
Not yet open
Oliver Cornely, MD
Phase 4
420
Aachen, Berlin, Cologne, Dresden, Düsseldorf, Frankfurt am Main, Freiburg im Breisgau, Giessen
2026-09
Recruiting
AstraZeneca
Phase 3
1,072
Berlin, Dresden, Essen, Freiburg im Breisgau, Hanover, Kiel, Mainz, Marburg
2026-08-31
Recruiting
Ascletis Pharma (China) Co., Limited
Phase 3
3,003
Berlin, Essen, Hanover, Leipzig
2026-08-31
Recruiting
Ascletis Pharma (China) Co., Limited
Phase 3
1,560
Berlin, Essen, Hanover
2026-08-28
By invitation
Online Socio-emotional Dyad Training for School Teachers' Well-being and Social Skills
NCT07637409Intervention (Training) Condition, Waitlist Control Group
Max Planck Social Neuroscience Lab
Not applicable
900
Berlin
2026-08-28
Recruiting
Eli Lilly and Company
Phase 3
2,001
Berlin, Bochum, Hanover, Hohenmölsen, Karlsruhe, Leipzig, Obertshausen, Offenbach
2026-08-26
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
DrugElecoglipron
AstraZeneca
Phase 3
6,950
Bad Oldesloe, Bamberg, Berlin, Bielefeld, Bochum, Bremen, Chemnitz, Cologne
2026-08-24
Recruiting
AstraZeneca
Phase 3
7,000
Ahrensburg, Bad Mergentheim, Bad Nenndorf, Berlin, Bonn, Brandenburg an der Havel, Braunschweig, Chemnitz
2026-08-21
Recruiting
AstraZeneca
Phase 3
1,500
Berlin, Bochum, Bünde, Dresden, Frankfurt, Freiburg im Breisgau, Göttingen, Hamburg
2026-08-20
Recruiting
AstraZeneca
Phase 3
2,500
Berlin, Bochum, Bünde, Dresden, Frankfurt, Freiburg im Breisgau, Göttingen, Hamburg
2026-08-19
Recruiting
Eli Lilly and Company
Phase 3
1,000
Berlin, Chemnitz, Hamburg, Leipzig, Schwerin
2026-08-14
Recruiting
AstraZeneca
Phase 3
600
Ahrensburg, Berlin, Bochum, Gladbeck, Hamburg, Hanover, Karlsruhe, Leipzig
2026-08-12
Recruiting
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
NCT07746895C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
DrugPegcetacoplan
Swedish Orphan Biovitrum
Phase 4
150
Aachen, Berlin, Cologne, Dresden, Erlangen, Essen, Hamburg, Hanover
2026-08-05
Not yet open
A Prospective Multicenter Cohort Study of Contemporary Menopausal Hormone Therapy and Cardiovascular Outcomes
NCT07394049Hormone Replacement Therapy, Cardiovascular Diseases, Hormone Replacement Therapy, Post-Menopausal, Menopause
Heinrich-Heine University, Duesseldorf
Observational
3,408
Berlin, Düsseldorf
2026-08-01
Recruiting
VectivBio AG
Phase 3
124
Heidelberg, Erlangen, Hamburg, Bonn, Essen, Münster, Aachen, Berlin
2026-08
Recruiting
Charite University, Berlin, Germany
Not applicable
60
Berlin
2026-07-28
Recruiting
Sanofi
Phase 2
160
Berlin, Cologne
2026-07-28
Recruiting
Guerbet
Phase 3
315
Berlin, Bonn, Detmold, Essen, Homburg, Kiel, Lübeck
2026-07-28
Not yet open
Master Study Protocol for the Cohort of the Specialist Network Stroke (SN Stroke)(Stroke-CORE)
NCT07553650Intracerebral Haemorrhage, Paediatric Stroke, Stroke Acute, Stroke
Charite University, Berlin, Germany
Observational
12,750
Hamburg, Berlin, Bielefeld, Dresden, Erlangen, Essen, Heidelberg, Leipzig
2026-07-27
Recruiting
Boehringer Ingelheim
Phase 3
448
Bad Bramstedt, Berlin, Dresden, Freiburg im Breisgau, Hanover, Heidelberg, Lübeck, Münster
2026-07-27
Recruiting
Boehringer Ingelheim
Phase 3
35
Berlin, Hamburg, Hanover
2026-07-21
Recruiting
Registry for Duchenne and Becker Muscular Dystrophy
NCT07402122Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy, Dystrophinopathy Symptomatic Female Carrier
Dr. Andreas Ziegler
Observational
1,500
Berlin, Bochum, Bonn, Bremen, Dresden, Erlangen, Essen, Freiburg im Breisgau
2026-07-13
Recruiting
Boehringer Ingelheim
Phase 3
390
Berlin, Bonn, Cologne, Dresden, Düsseldorf, Erlangen, Freiburg im Breisgau, Hamburg
2026-07-10
Recruiting
AstraZeneca
Phase 3
600
Amberg, Bad Oeynhausen, Berlin, Bochum, Brandenburg an der Havel, Daaden, Duisburg, Eisenach
2026-07-08
Recruiting
Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM
NCT07690436Transthyretin Amyloid Cardiomyopathy
AstraZeneca
Observational
500
Berlin, Essen, Frankfurt am Main, Würzburg
2026-07-08
Recruiting
AstraZeneca
Phase 3
1,200
Bad Oeynhausen, Berlin, Chemnitz, Damme, Duisburg, Elsterwerda, Erlangen, Essen
2026-07-06
Recruiting
AstraZeneca
Phase 3
2,000
Berlin, Cologne, Damme, Deggingen, Duisburg, Essen, Falkensee, Frankfurt
2026-07-06
Recruiting
AstraZeneca
Phase 3
900
Bad Oeynhausen, Berlin, Brandenburg an der Havel, Chemnitz, Duisburg, Erlangen, Frankfurt, Hamburg
2026-07-06
Recruiting
Insel Gruppe AG, University Hospital Bern
Phase 3
400
Berlin
2026-07-02
Recruiting
Scapholunate Ligament Reconstruction Using Modified Flexor Carpi Radialis Tenodesis
NCT07667114Scapholunate Dissociation, Scapholunate Ligament Rupture
Waldfriede Hospital
Observational
100
Berlin
2026-07-01
Recruiting
Universität Duisburg-Essen
Not applicable
346
Berlin, Bonn, Cologne, Essen, Frankfurt, Hamburg, Jena, Mainz
2026-07-01
Not yet open
Educational Video to Improve Understanding and Reduce Anxiety in Heart Attack Patients
NCT07424482Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI), Anxiety, Patient Education Materials
Tobias Schreiber
Not applicable
140
Berlin
2026-07-01
Not yet open
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
101
Berlin, Cologne, Essen, Frankfurt am Main, Göttingen, Halle, Hamburg, Heidelberg
2026-07-01
Recruiting
Merck Sharp & Dohme LLC
Phase 2
750
Konstanz, Erlangen, Munich, Kassel, Offenbach, Stuhr, Dresden, Berlin
2026-06-30
Recruiting
Hoffmann-La Roche
Phase 1
25
Berlin
2026-06-29
Recruiting
AstraZeneca
Phase 3
750
Berlin, Cologne, Dresden, Essen, Freiburg im Breisgau, Hamburg, Kiel, Leipzig
2026-06-26
Recruiting
Edwards Lifesciences
Observational
250
München, Bonn, Berlin
2026-06-25
Recruiting
Kymera Therapeutics, Inc.
Phase 2
264
Berlin
2026-06-25
Recruiting
Hoffmann-La Roche
Phase 3
380
Bad Saarow, Berlin, Düsseldorf, Frankfurt, Greifswald, Kiel
2026-06-23
Recruiting
Novo Nordisk A/S
Phase 2
300
Amberg, Bad Oeynhausen, Berlin, Bochum, Bünde, Essen, Hof, Mannheim
2026-06-22
Recruiting
Charite University, Berlin, Germany
Phase 3
320
Berlin, Augsburg, Frankfurt, Freiburg im Breisgau, Hamburg, Leipzig, München, Stralsund
2026-06-22
Recruiting
Laurenz Kopp Fernandes
Observational
30
Berlin
2026-06-18
Recruiting
Novo Nordisk A/S
Phase 1
32
Berlin
2026-06-17
Recruiting
AstraZeneca
Phase 3
150
Berlin, Düsseldorf, Erlangen, Freiburg im Breisgau, Mönchengladbach, München, Paderborn, Trier
2026-06-15
Active, closed
AstraZeneca
Phase 2
326
Berlin, Cologne, Essen, Hamburg, Heidelberg, Homburg, München, Münster
2026-06-11
Recruiting
AstraZeneca
Observational
200
Berlin, Bochum, Braunschweig, Dortmund, Dresden, Erfurt, Göppingen, Hagen
2026-06-10
Active, closed
Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9
NCT07678775Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
DrugRibitol
ML Bio Solutions, Inc.
Phase 3
107
Berlin
2026-06-05
Recruiting
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
Phase 3
320
Berlin, Bonn, Gera, Göttingen, Halle, Karlsruhe, Recklinghausen, Rostock
2026-06-05
Recruiting
Charite University, Berlin, Germany
Observational
100,000
Berlin
2026-06-03
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Munich, Würzburg, Bonn, Düsseldorf, Dresden, Leipzig, Beelitz, Berlin
2026-06-03
Recruiting
Dompé Farmaceutici S.p.A
Phase 3
150
Erlangen, Frankfurt am Main, Marburg, Cologne, Düsseldorf, Homburg, Berlin
2026-06-02
Recruiting
Impact of Shift Work on Glucose and Lipid Metabolism of Hospital Workers
NCT07426211Chronodisruption, Shift Work Disorder, Glucose and Lipid Metabolism
Olga Ramich (formerly Pivovarova)
Observational
48
Berlin
2026-06-01
Recruiting
Charite University, Berlin, Germany
Observational
50
Berlin
2026-06-01
Not yet open
Matthias Stuber
Observational
300
Bonn, Cologne, Berlin
2026-06
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Eli Lilly and Company
Phase 1
215
Berlin, München, Münster
2026-05-28
Recruiting
FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis
NCT07645443Delusional Disorder, Brief Psychotic Disorder, Schizophreniform Disorder, Schizophrenia / Schizoaffective Disorder
Stephanie Mehl
Not applicable
252
Mannheim, Augsburg, München, Hamburg, Marburg, Cologne, Berlin
2026-05-27
Recruiting
Janssen Research & Development, LLC
Phase 3
644
Berlin, Dachau, Dresden, Erlangen, Halle, Hanover, Jena, Kassel
2026-05-23
Recruiting
AbbVie
Phase 3
990
Reutlingen, Munich, Dresden, Berlin, Hamburg
2026-05-22
Recruiting
Janssen Research & Development, LLC
Phase 3
460
Augsburg, Berlin, Dachau, Dresden, Erlangen, Halle, Hanover, Kassel
2026-05-22
Recruiting
BeOne Medicines
Phase 3
1,056
Berlin, Esslingen am Neckar, Frankfurt am Main, Koblenz
2026-05-22
Recruiting
Alfasigma S.p.A.
Phase 3
65
Berlin, Hamburg
2026-05-21
Recruiting
Takeda
Phase 3
300
Bayreuth, Münster, Halle, Berlin
2026-05-21
Recruiting
Incyte Corporation
Phase 2
60
Berlin, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Hanover, Regensburg
2026-05-20
Recruiting
Jade Biosciences, Inc.
Phase 1
36
Berlin
2026-05-19
Recruiting
Novo Nordisk A/S
Phase 1
234
Berlin
2026-05-18
Recruiting
Takeda
Phase 2
222
Heidelberg, Tübingen, Potsdam, Frankfurt am Main, Göttingen, Dresden, Berlin
2026-05-17
Recruiting
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
NCT07486934Myotonic Dystrophy Type 1 (DM1), DM1, Myotonic Dystrophy, Steinert Disease
DrugZeleciment basivarsen
Dyne Therapeutics
Phase 3
150
Munich, Göttingen, Bonn, Berlin
2026-05-14
Recruiting
Ipsen
Phase 3
350
Berlin, Dresden, Hanover, Heidelberg, Leipzig, Magdeburg, Mainz, Tübingen
2026-05-14
Recruiting
Eli Lilly and Company
Phase 2
600
Bergisch Gladbach, Berlin, Bielefeld, Bochum, Bonn, Bottrop, Bremen, Cottbus
2026-05-13
Recruiting
Sanofi
Phase 3
300
Berlin, Freiburg im Breisgau, Hamburg, Herne, Neubrandenburg, Würzburg
2026-05-12
Recruiting
Incyte Corporation
Phase 1
218
Aachen, Berlin, Freiburg im Breisgau, Halle, Mainz
2026-05-11
Recruiting
Novo Nordisk A/S
Phase 3
5,610
Aachen, Bad Friedrichshall, Bad Oeynhausen, Berlin, Bochum, Coburg, Cologne, Dresden
2026-05-11
Recruiting
Universitätsklinikum Hamburg-Eppendorf
Not applicable
446
Berlin, Düsseldorf, Hamburg, München
2026-05-07
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 3
1,020
Frankfurt am Main, Leipzig, Berlin, Hamburg
2026-05-06
Recruiting
Eli Lilly and Company
Phase 2
531
Berlin, Dachau, Hamburg, Karlsruhe, Leipzig, Offenbach
2026-05-06
Recruiting
AstraZeneca
Phase 3
670
Augsburg, Berlin, Bonn, Cologne, Dresden, Essen, Jena, Karlsruhe
2026-05-04
Recruiting
Eli Lilly and Company
Phase 2
60
Berlin, Dachau, Halle, Ludwigshafen, Ulm
2026-05-04
Recruiting
Eli Lilly and Company
Phase 2
60
Berlin, Dachau, Halle, Ludwigshafen, Ulm
2026-05-04
Not yet open
Nexira
Not applicable
24
Berlin
2026-05
Recruiting
Novo Nordisk A/S
Phase 1
120
Berlin
2026-04-30
Recruiting
Aarhus University Hospital
Phase 1
15
Berlin
2026-04-23
Recruiting
Echosens
Not applicable
149
Berlin
2026-04-23
Recruiting
Merck Sharp & Dohme LLC
Phase 3
590
Berlin
2026-04-23
Recruiting
Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe
NCT07585890End-stage Liver Disease (ESLD), Acute Liver Failure, Liver Cirrhosis, Liver Transplantation
University Medical Center Groningen
Observational
10,000
Aachen, Berlin, Bonn, Essen, Hanover, Heidelberg, Magdeburg, München
2026-04-21
Recruiting
Janssen Research & Development, LLC
Phase 3
530
Berlin, Erlangen, Grevenbroich, Jena, Kiel, Ludwigshafen am Rhein, Mannheim, München
2026-04-21
Recruiting
Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their Support Persons
NCT07788729Cancer, Lung Cancer, Colorectal Cancer, Hematological Cancer
University of Regensburg
Not applicable
384
Augsburg, Erlangen, Regensburg, Würzburg, Bayreuth, Berlin, Cologne
2026-04-21
Active, closed
Merck Sharp & Dohme LLC
Phase 2
140
Cottbus, Herne, Berlin, Hamburg
2026-04-20
Recruiting
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 3
420
Berlin, Bonn, Dresden, Düsseldorf, Tübingen
2026-04-17
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
DrugRituximab
Eli Lilly and Company
Phase 1
460
Berlin, Cologne, Essen, Frankfurt am Main
2026-04-17
Recruiting
Boehringer Ingelheim
Phase 3
670
Aachen, Berlin, Berlin-Spandau, Dresden, Essen, Frankfurt, Freiburg im Breisgau, Gauting
2026-04-13
Recruiting
DEfeating PEnile CAncer-2
NCT07378670Penile Cancer, Penile Neoplasms Malignant
University Hospital Tuebingen
Not applicable
80
Berlin, Dresden, Erlangen, Mainz, Mannheim, München, Rostock, Tübingen
2026-04-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
758
Augsburg, Munich, Jena, Berlin
2026-04-09
Recruiting
Incyte Corporation
Phase 3
588
Berlin, Bochum, Bonn, Cologne, Dresden, Düsseldorf, Essen, Frankfurt
2026-04-09
Active, closed
Pfizer
Observational
1
Berlin
2026-04-02
Not yet open
University of Leipzig
Observational
100
Berlin, Frankfurt, Hamburg, Hanover, Heidelberg, Herne, Homburg, Jena
2026-04-01
Recruiting
Philipps University Marburg
Not applicable
3,369
Augsburg, Bad Neustadt an der Saale, Berlin, Cologne, Düsseldorf, Erlangen, Frankfurt, Giessen
2026-04-01
Recruiting
MB-CART2019.1 in Refractory Multiple Sclerosis
NCT07178431Multiple Sclerosis, CAR T Cell Therapy
DrugZamtocabtagene autoleucel
Miltenyi Biomedicine GmbH
Phase 1/2
26
Berlin
2026-04-01
Not yet open
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
20
Heidelberg, Düsseldorf, Essen, Münster, Berlin
2026-04
Recruiting
Comprehensive LEFt Atrial Appendage Occlusion With Rhythm Restoration
NCT07523620Atrial Fibrillation (AF), Paroxysmal AF, Persistent Atrial Fibrillation
Abbott Medical Devices
Not applicable
240
Frankfurt am Main, Lübeck, Berlin
2026-03-31
Recruiting
Novo Nordisk A/S
Phase 1
120
Berlin
2026-03-30
Recruiting
Renaissance Pharma Ltd.
Phase 2/3
144
Berlin
2026-03-30
Recruiting
Eisai Inc.
Phase 2
64
Bayern, Berlin, Marburg, Schwerin
2026-03-26
Recruiting
Boehringer Ingelheim
Phase 2
132
Berlin, Cologne, Hamburg, Hanover, Mainz, München
2026-03-23
Recruiting
Amgen
Phase 3
406
Berlin, Essen, Frankfurt am Main, München
2026-03-23
Recruiting
Freya Biosciences ApS
Phase 2
120
Berlin, Mannheim
2026-03-23
Recruiting
AstraZeneca
Observational
125
Altenburg, Bad Bramstedt, Bamberg, Berlin, Braunschweig, Chemnitz, Erlangen, Hanover
2026-03-19
Recruiting
University Hospital, Essen
Observational
180
Berlin, Bochum, Essen, Hamburg, Heidelberg, Münster
2026-03-18
Recruiting
SymBio Pharmaceuticals
Phase 3
180
Berlin, Essen, Frankfurt, Freiburg im Breisgau, Hamburg, Hanover, Münster, Tübingen
2026-03-17
Recruiting
Bristol-Myers Squibb
Phase 3
850
Augsburg, Erlangen, Koblenz, Ludwigshafen am Rhein, Magdeburg, Kiel, Jena, Berlin
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 2/3
690
Berlin, Frankfurt, Hamburg, Heidelberg, Leipzig, Mainz, Mannheim, Ulm
2026-03-13
Recruiting
Observational Study on Immunoadsorption (IA) in Patients With Autoantibody-Positive Post-Infectious ME/CFS
NCT07529197Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), ME/CFS Following COVID-19
Charite University, Berlin, Germany
Observational
50
Berlin
2026-03-11
Recruiting
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
NCT07332481Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
DrugEnpatoran
EMD Serono Research & Development Institute, Inc.
Phase 3
202
Buxtehude, Berlin, Dresden
2026-03-10
Recruiting
Charite University, Berlin, Germany
Observational
35,000
Berlin
2026-03-05
Recruiting
Incyte Corporation
Phase 3
700
Berlin, Dresden, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Hanover, Lübeck
2026-03-05
Active, closed
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
NCT07288398Pulmonary Hypertension Associated With HFpEF
DrugTNX-103
Tenax Therapeutics, Inc.
Phase 3
540
Bad Bevensen, Bad Nauheim, Berlin, Dresden, Hamburg, Jena, Mainz
2026-03-03
Recruiting
University Hospital Schleswig-Holstein
Phase 2
390
Berlin, Kiel, Leipzig, Lübeck, München, Tübingen
2026-03-03
Recruiting
Timo Munz
Observational
543
Amberg, Berlin, Chemnitz, Dresden, Duisburg, Freiburg im Breisgau, Hamburg, Kassel
2026-03-02
Recruiting
Non-invasive Brain Stimulation in Multiple Sclerosis Fatigue
NCT07438964Multiple Sclerosis, Fatigue in Multiple Sclerosis
Charite University, Berlin, Germany
Not applicable
84
Berlin
2026-03-02
Not yet open
Multicentric Approval Study Trans-Duodenal Barrier for Typ 2 Diabetes With Obesity
NCT07417683Typ 2 Diabetes, Obesity, Obesity Type 2 Diabetes Mellitus, MASH
Trans-Duodenal Concepts GmbH
Not applicable
126
Mannheim, Bamberg, Würzburg, Bochum, Dresden, Leipzig, Berlin
2026-03
Recruiting
Charite University, Berlin, Germany
Not applicable
60
Berlin
2026-03
Active, closed
Pfizer
Phase 3
1,078
Munich, Leipzig, Berlin, Dresden, Essen, Hamburg, Holstein, Karlsruhe
2026-02-24
Recruiting
AstraZeneca
Phase 3
508
Berlin, Dresden, Erlangen, Essen, Freiburg im Breisgau, Hamburg, Leipzig, Mainz
2026-02-23
Recruiting
Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy
NCT07461220PARKINSON DISEASE (Disorder), Apathy, Safety
Integrative Research Laboratories AB
Phase 1/2
75
Berlin, Dresden
2026-02-18
Active, closed
Online Socio-emotional Dyad Training for Healthcare Students' Well-being and Social Skills
NCT07407413Intervention Condition, Control (Delayed Training) Condition
Max Planck Social Neuroscience Lab
Not applicable
360
Berlin
2026-02-16
Recruiting
Boehringer Ingelheim
Phase 3
286
Berlin, Cologne, Hamburg, Hanover, Heidelberg, Leipzig, Mainz, Würzburg
2026-02-16
Recruiting
Bayer
Phase 4
50
Ulm, Darmstadt, Greifswald, Bonn, Berlin, Hamburg
2026-02-13
Recruiting
Pfizer
Phase 2/3
1,156
Essen, Bendorf, Berlin, Delitzsch, Frankfurt, Leipzig
2026-02-11
Recruiting
ViiV Healthcare
Phase 2
186
Frankfurt am Main, Berlin, Cologne, Hamburg, München
2026-02-11
Recruiting
Zealand Pharma
Phase 3
90
Rostock, Leipzig, Aachen, Berlin, Bonn, Hamburg
2026-02-11
Recruiting
PICS Clinic Attendance and Recovery Engagement (PICS-CARE)
NCT07371741Post-intensive Care Syndrome
Charite University, Berlin, Germany
Observational
2,500
Berlin
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
800
Bamberg, Berlin, Essen, Hanover, Karlsruhe, Marburg, Oldenburg, Schwerin
2026-02-10
Recruiting
Pfizer
Phase 1/2
224
Heidelberg, Dresden, Berlin
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
1,000
Aachen, Berlin, Bielefeld, Chemnitz, Mainz, Mannheim, Schwerin, Siegen
2026-02-09
Recruiting
AO Foundation, AO Spine
Observational
260
Berlin
2026-02-09
Recruiting
Chong Kun Dang Pharmaceutical
Phase 1
519
Berlin
2026-02-09
Recruiting
Medical University of Vienna
Observational
5,000
Augsburg, Würzburg, Berlin
2026-02-04
Recruiting
AstraZeneca
Phase 3
2,130
Augsburg, Bad Saarow, Berlin, Bonn, Dresden, Essen, Frankfurt, Freiburg im Breisgau
2026-02-03
Recruiting
Alnylam Pharmaceuticals
Phase 3
125
Berlin, Heidelberg, Münster
2026-02-03
Recruiting
Exciva GmbH
Phase 2/3
300
Böblingen, Ebersberg, München, Berlin
2026-02-02
Recruiting
Prilenia
Phase 3
500
Berlin, Bonn, Hanover, Jena, Lübeck, Ulm
2026-02-01
Recruiting
Genmab
Phase 2
240
Berlin, Essen, Halle, Heidelberg
2026-01-30
Recruiting
Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders
NCT07395206Psychosis, Psychotic Disorders, Primary Psychotic Disorders, Schizophrenia Spectrum Disorders
Charite University, Berlin, Germany
Not applicable
60
Berlin
2026-01-30
Active, closed
A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy
NCT07363720Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy
DrugTAK-861
Takeda
Phase 3
98
Schwerin, Berlin
2026-01-29
By invitation
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
NCT07474051B-cell Lymphoma, Chronic Lymphocytic Leukemia, Hematologic Malignancy, AML (Acute Myelogenous Leukemia)
DrugAllo-QuadCAR01-T
AvenCell Therapeutics, Inc.
Observational
178
Berlin, Dresden, Marburg, Munich, Ulm
2026-01-29
Recruiting
Kymera Therapeutics, Inc.
Phase 2
264
Berlin, Leipzig
2026-01-28
Active, closed
Takeda
Phase 2
91
Bad Bentheim, Bochum, Mainz, Berlin
2026-01-26
Recruiting
IDEAYA Biosciences
Phase 3
520
Tübingen, Ulm, Erlangen, Essen, Dessau, Berlin, Bonn, Lübeck
2026-01-25
Recruiting
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
NCT07159841Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
DrugAtumelnant
Crinetics Pharmaceuticals Inc.
Phase 2/3
153
Tübingen, Cologne, Berlin
2026-01-22
Recruiting
Technische Universität Dresden
Phase 2
220
Aachen, Augsburg, Berlin, Chemnitz, Cologne, Dresden, Frankfurt am Main, Greifswald
2026-01-21
Recruiting
Eikon Therapeutics
Phase 1/2
160
Deggendorf, Berlin, Hamburg
2026-01-20
Active, closed
Janssen Research & Development, LLC
Phase 2
189
Berlin, Bramsche, München, Münster
2026-01-20
Recruiting
Charite University, Berlin, Germany
Not applicable
40
Berlin
2026-01-20
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,023
Jena, Berlin, Hamburg
2026-01-19
Recruiting
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
80
Berlin, Bielefeld, Dresden, Essen, Frankfurt, Göttingen, Hamburg, Herne
2026-01-16
Recruiting
Sanofi
Phase 3
751
Tübingen, Ulm, Leipzig, Halle, Kiel, Berlin, Minden
2026-01-16
Recruiting
Boehringer Ingelheim
Phase 3
400
Berlin, Cologne, Esslingen am Neckar, Frankfurt, Gauting, Großhansdorf, Heidelberg, Oldenburg
2026-01-16
Recruiting
German Heart Institute
Not applicable
45
Berlin, Frankfurt am Main
2026-01-15
Active, closed
Janssen Research & Development, LLC
Phase 2
157
Bad Bentheim, Berlin, Cottbus, Hamburg, Heidelberg, Mainz, Remscheid, Witten
2026-01-15
Recruiting
Celldex Therapeutics
Phase 3
240
Augsburg, Berlin, Buxtehude, Darmstadt, Dresden, Düsseldorf, Erlangen, Göttingen
2026-01-15
Recruiting
A Study of AZD0120 in Autoimmune Diseases
NCT07295847Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
DrugAZD0120
AstraZeneca
Phase 1/2
27
Berlin, Erlangen, Hamburg, Jena, Mainz, Würzburg
2026-01-09
Recruiting
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
NCT07284433Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma, Leukemia Relapse, Lymphoma Receiving CAR-T Therapy
DrugAllo-QuadCAR01-T
AvenCell Therapeutics, Inc.
Phase 1/2
178
Ulm, Erlangen, Munich, Marburg, Essen, Dresden, Berlin, Hamburg
2026-01-06
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
München, Frankfurt am Main, Kassel, Georgsmarienhütte, Chemnitz, Halle, Lübeck, Berlin
2026-01-06
Recruiting
Biogen
Phase 2
81
Berlin, Dresden, Hamburg, Regensburg
2026-01-05
Recruiting
Amgen
Phase 2
14
Berlin
2026-01-02
Recruiting
Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease
NCT07299994Stroke, Thrombolysis, DAPT(Dual Antiplatelet Therapy), SAPT(Single Antiplatelet Therapy)
Sigmund Freud PrivatUniversitat
Observational
462
Berlin, Heidelberg, Tübingen
2026-01-01
Recruiting
Charite University, Berlin, Germany
Observational
100
Berlin
2026-01-01
Recruiting
Bristol-Myers Squibb
Phase 2/3
990
Erlangen, Hanover, Dresden, Berlin, Bochum, Chemnitz, Düsseldorf, Frankfurt
2025-12-31
Recruiting
Norgine
Phase 3
212
Regensburg, Münster, Wuppertal, Mainz, Berlin
2025-12-29
Recruiting
AstraZeneca
Phase 3
1,100
Berlin, Bonn, Detmold, Dresden, Düsseldorf, Essen, Frankfurt am Main, Hamburg
2025-12-29
Recruiting
Mylan Pharmaceuticals Inc
Phase 2
60
Berlin
2025-12-22
Recruiting
Eli Lilly and Company
Phase 3
800
Berlin, Bottrop, Cologne, Dessau, Donauwörth, Dresden, Erlangen, Essen
2025-12-22
Recruiting
argenx
Observational
70
Berlin, Göttingen, Würzburg
2025-12-19
Recruiting
argenx
Phase 2
70
Berlin, Göttingen, Würzburg
2025-12-19
Active, closed
Pfizer
Phase 3
3,578
Munich, Leipzig, Bad Homburg, Berlin, Dresden, Essen, Hamburg, Holstein
2025-12-19
Active, closed
Amgen
Phase 3
250
Berlin, Essen, Hamburg, Hanover, Karlsruhe, Oldenburg
2025-12-19
Recruiting
UNICANCER
Phase 3
3,902
Aachen, Augsburg, Bad Nauheim, Berlin, Bremen, Cottbus, Dresden, Düsseldorf
2025-12-18
Recruiting
Ipsen
Observational
150
Aschaffenburg, Berlin, Bonn, Bremen, Chemnitz, Cologne, Dresden, Erlangen
2025-12-17
Recruiting
Chiesi Farmaceutici S.p.A.
Phase 2
780
Ahrensburg, Berlin, Cottbus, Delitzsch, Düsseldorf, Hamburg, Ibbenbueren, Leipzig
2025-12-17
Active, closed
WATCHMAN FLX Pro European Registry
NCT07262255Non-valvular Atrial Fibrillation (AF), Left Atrial Appendage Closure
Boston Scientific Corporation
Observational
189
Bad Oeynhausen, Berlin, Erfurt, Hamburg, Lübeck
2025-12-17
Recruiting
University of Cologne
Phase 3
420
Stuttgart, Nuremberg, Aachen, Berlin, Cologne, Dortmund, Dresden, Düsseldorf
2025-12-16
Recruiting
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
33
Amberg, Berlin, Düsseldorf, Essen, Frankfurt am Main, Hamburg, Mainz, München
2025-12-16
Recruiting
AstraZeneca
Phase 2
320
Bad Doberan, Berlin, Hamburg, Sendenhorst
2025-12-15
Recruiting
Eli Lilly and Company
Phase 3
1,035
Berlin, Bünde, Essen, Hamburg, Münster, Oldenburg
2025-12-15
Recruiting
Pfizer
Phase 3
800
Frankfurt am Main, Essen, Leipzig, Berlin, Dresden, Hamburg, München
2025-12-11
Active, closed
Zealand Pharma
Phase 3
28
Frankfurt am Main, Rostock, Bonn, Berlin, Hamburg
2025-12-11
Recruiting
AstraZeneca
Phase 2
230
Augsburg, Berlin, Cologne, Frankfurt, Hamburg, Jena, Leipzig, München
2025-12-10
Recruiting
Protara Therapeutics
Phase 2/3
129
Berlin, Essen
2025-12-10
Recruiting
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
NCT06793397Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders
DrugCYB003
Cybin IRL Limited
Phase 3
330
Homburg, Berlin, Frankfurt am Main, Mannheim
2025-12-10
Recruiting
UCB Biopharma SRL
Phase 1
392
Berlin, Hamburg, Ratingen, Wetzlar
2025-12-10
Recruiting
Incyte Corporation
Phase 3
466
Berlin, Bonn, Dresden, Essen, Kassel, Kiel, Mannheim, Minden
2025-12-09
Recruiting
Blueprint Medicines Corporation
Observational
80
Berlin, Bochum, Deggendorf, Dresden, Freiburg im Breisgau, Göttingen, Leipzig, Munich
2025-12-09
Recruiting
Christian Schulze
Phase 3
536
Jena, Bad Nauheim, Berlin, Bonn, Dresden, Göttingen, Halle, Leipzig
2025-12-08
Recruiting
AstraZeneca
Phase 3
1,100
Aachen, Berlin, Bonn, Düsseldorf, Essen, Frankfurt, Freiburg im Breisgau, Hamburg
2025-12-04
Recruiting
Merck Sharp & Dohme LLC
Phase 2
150
Leipzig, Jena, Berlin
2025-12-04
Recruiting
Generate Biomedicines
Phase 3
786
Deggingen, München, Frankfurt am Main, Witten, Leipzig, Lübeck, Berlin
2025-12-03
Recruiting
GlaxoSmithKline
Phase 3
450
München, Cologne, Essen, Dresden, Berlin, Mannheim, Tübingen
2025-12-03
Recruiting
Bristol-Myers Squibb
Phase 3
366
Münster, Mainz, Berlin, Dresden, Erlangen
2025-12-03
Recruiting
Sanofi
Phase 2
37
Berlin
2025-12-02
Active, closed
Novartis Pharmaceuticals
Phase 2
234
Munich, Potsdam, Frankfurt am Main, Kaiserslautern, Dresden, Bad Krozingen, Bad Oeynhausen, Berlin
2025-12-02
Recruiting
Eli Lilly and Company
Phase 1
141
Berlin
2025-12-02
Recruiting
Prof. Dr. Martin Wabitsch
Observational
70
Berlin, Leipzig, Ulm
2025-12-01
Not yet open
Charite University, Berlin, Germany
Observational
13
Berlin
2025-12
Not yet open
WELT corp
Not applicable
80
Berlin
2025-12
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Frankfurt am Main, Berlin, Cologne, Dresden, Halle, Hamburg
2025-11-30
Recruiting
Amgen
Phase 3
750
Berlin, Bonn, Dresden, Erlangen, Essen, Hamburg, Heidelberg, Jena
2025-11-28
Recruiting
Genmab
Phase 3
660
Hamburg, Wiesbaden, Bonn, Lemgo, Berlin
2025-11-28
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
135
Berlin, Darmstadt, Leipzig, Mainz
2025-11-27
Recruiting
Debiopharm International SA
Phase 3
119
Berlin, Munich, Würzburg
2025-11-26
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 2
78
Berlin, Göttingen, Ludwigshafen
2025-11-26
Active, closed
Amgen
Phase 3
250
Berlin, Essen, Hamburg, Hanover, Karlsruhe, Oldenburg
2025-11-25
Recruiting
AbbVie
Phase 2
180
Immenhausen, Marburg, Berlin
2025-11-25
Recruiting
PhenoNet, Inc.
Phase 2
105
Berlin, Hanover, Lübeck
2025-11-25
Recruiting
AstraZeneca
Phase 4
56
Ahrensburg, Berlin, Frankfurt, Hanover
2025-11-24
Recruiting
Hoffmann-La Roche
Phase 3
900
Beelitz, Berlin, Bochum, Dresden, Düsseldorf, Erlangen, Freiburg im Breisgau, Hanover
2025-11-24
Recruiting
Novartis Pharmaceuticals
Phase 1
112
Berlin
2025-11-20
Active, closed
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
NCT07161037Autosomal Dominant Polycystic Kidney Disease (ADPKD)
DrugVX-407
Vertex Pharmaceuticals Incorporated
Phase 2
26
Berlin, Cologne
2025-11-19
Active, closed
Bayer
Phase 2
60
Erlangen, Göttingen, Cologne, Berlin
2025-11-19
Recruiting
Summit Therapeutics
Phase 3
900
Berlin, Bonn, Hamburg
2025-11-18
Recruiting
UCB Biopharma SRL
Phase 3
320
Ahaus, Bad Bentheim, Berlin, Bielefeld, Bochum, Dresden, Göttingen, Kiel
2025-11-14
Recruiting
Incyte Corporation
Phase 3
250
Berlin, Erlangen, Hamburg, Kiel, Leipzig, Mainz, München, Münster
2025-11-13
Active, closed
Hoffmann-La Roche
Phase 2
193
Berlin, Bochum, Dresden, Tübingen
2025-11-13
Active, closed
Hoffmann-La Roche
Phase 3
1,060
Erlangen, Berlin, Bonn, Cologne, Dresden, Homburg/Saar, Jena, Leipzig
2025-11-12
Recruiting
AstraZeneca
Phase 3
420
Berlin, Dresden, Rostock
2025-11-11
Recruiting
Eli Lilly and Company
Phase 2
252
Berlin, Dachau, Erlangen, Regensburg, Ulm
2025-11-10
Recruiting
BIONCaRT GmbH
Phase 1/2
55
Altenburg, Andernach, Bamberg, Berlin, Dinslaken, Dresden, Greven
2025-11-10
Active, closed
Novartis Pharmaceuticals
Phase 2
34
Berlin, Hamburg, Mainz
2025-11-10
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
65
Freiburg im Breisgau, Ulm, Cologne, Essen, Chemnitz, Berlin, Göttingen, Hamburg
2025-11-06
Recruiting
AstraZeneca
Phase 2
435
Berlin, Darmstadt, Essen, Frankfurt, Halle, Hanover, Konstanz, München
2025-11-06
Recruiting
Bristol-Myers Squibb
Phase 2/3
661
Esslingen am Neckar, Stuttgart, Donauwörth, Oldenburg, Cologne, Chemnitz, Kiel, Berlin
2025-11-05
Recruiting
Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA
NCT07089576Aortic Arch Aneurysm, Aortic Arch Dissection, Chronic Aortic Dissection, Acute Aortic Dissection
Artivion Inc.
Not applicable
132
Berlin, Freiburg im Breisgau, Leipzig
2025-11-04
Recruiting
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
NCT07197307Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL), Follicular Lymphoma (FL) Grade 3B
Universität Münster
Phase 2
120
Aachen, Augsburg, Berlin, Bielefeld, Chemnitz, Düsseldorf, Erlangen, Essen
2025-10-31
Recruiting
Pfizer
Phase 2
200
Stuttgart, Münster, Berlin, Dresden, Leipzig, Marburg, Wuppertal
2025-10-30
Recruiting
GlaxoSmithKline
Phase 2
363
Bendorf, Berlin, Frankfurt, Geesthacht, Hamburg, München
2025-10-30
Recruiting
Universität des Saarlandes
Phase 3
214
Berlin, Chemnitz, Darmstadt, Dresden, Erfurt, Erlangen, Frankfurt am Main, Giessen
2025-10-30
Recruiting
Novartis Pharmaceuticals
Phase 2
165
Bad Homburg, Berlin, Hamburg
2025-10-28
Recruiting
Novartis Pharmaceuticals
Phase 3
12
Cologne, Berlin
2025-10-28
Recruiting
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
140
Amberg, Bad Saarow, Berlin, Bochum, Düsseldorf, Essen, Frankfurt, Frankfurt am Main
2025-10-27
Recruiting
University Hospital Tuebingen
Phase 3
150
Saarlouis, Berlin, Bottrop, Dresden, Marburg, Tübingen, Wolfach
2025-10-27
Recruiting
Sanofi
Phase 3
60
Berlin, Dresden, Essen, Frankfurt am Main, Leipzig
2025-10-24
Recruiting
Hoffmann-La Roche
Phase 3
600
Berlin, Dresden, Essen, Esslingen am Neckar, Gauting, Großhansdorf, Halle, Hamburg
2025-10-24
Active, closed
Bristol-Myers Squibb
Phase 2/3
470
München, Frankfurt am Main, Göttingen, Bochum, Chemnitz, Dresden, Berlin, Cologne
2025-10-23
Recruiting
Novo Nordisk A/S
Phase 1
30
Berlin, Bonn, Hanover
2025-10-23
Recruiting
Eli Lilly and Company
Phase 2
531
Bendorf, Berlin, Essen, Frankfurt, Hamburg, Leipzig, Mainz, Offenbach
2025-10-22
Recruiting
Eli Lilly and Company
Phase 3
1,630
Aachen, Berlin, Bonn, Cologne, Dresden, Düsseldorf, Erlangen, Essen
2025-10-22
Recruiting
Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.
NCT07407465Colorectal Cancer, Colorectal Adenocarcinoma, Rectal Adenocarcinoma, Rectal Cancer, Adenocarcinoma
DrugsTrastuzumab deruxtecan·Capecitabine·Bevacizumab
Gruppo Oncologico del Nord-Ovest
Phase 2
42
Berlin, Frankfurt
2025-10-20
Recruiting
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
NCT07194850Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP, Immune Thrombocytopenic Purpura
DrugEfgartigimod
argenx
Phase 2/3
24
Berlin, Freiburg im Breisgau
2025-10-20
Recruiting
GlaxoSmithKline
Phase 3
1,196
Berlin, Frankfurt, Mainz, München
2025-10-20
Recruiting
Pharvaris Netherlands B.V.
Phase 3
48
Berlin, Frankfurt am Main, Munich
2025-10-16
Recruiting
Eli Lilly and Company
Phase 3
1,100
Berlin, Dresden, Hamburg, Mannheim, Offenbach, Schwerin
2025-10-16
Recruiting
Eli Lilly and Company
Phase 3
4,500
Bad Oeynhausen, Berlin, Brandenburg, Dresden, Düsseldorf, Frankfurt, Hanover, Heidelberg
2025-10-15
Recruiting
Vega Therapeutics, Inc
Phase 3
60
Berlin, Frankfurt
2025-10-15
Recruiting
Eli Lilly and Company
Phase 3
1,100
Berlin, Dresden, Hamburg, Mannheim, Offenbach, Schwerin
2025-10-15
Recruiting
Abalos Therapeutics GmbH
Phase 1
27
Berlin, Tübingen
2025-10-14
By invitation
Clinical Impact Through AI-assisted MS Care - A Prospective Multi-center Study
NCT07032246Multiple Sclerosis, Radiologically Isolated Syndrome, Clinically Isolated Syndrome
icometrix
Not applicable
750
Bochum, Dresden, Berlin
2025-10-09
Recruiting
Novartis Pharmaceuticals
Phase 2
140
Freiburg im Breisgau, Düsseldorf, Leipzig, Halle, Berlin, Stuttgart
2025-10-09
Active, closed
Merck Sharp & Dohme LLC
Phase 2
185
München, Cottbus, Ratingen, Berlin, Hamburg
2025-10-08
Recruiting
Sanofi
Phase 3
980
Wolfsburg, Halle, Berlin, Herne, Kiel, Leipzig, Minden, Ulm
2025-10-08
Recruiting
Study to Evaluate the Performance of Navigated TKA With OrthoPilot® pheno4u TKA Level 1
NCT06955481Osteoarthritis, Knee, Joint Diseases, Rheumatoid Arthritis of Knee, Posttraumatic Arthropathy
Aesculap AG
Observational
120
Konstanz, Berlin, Dresden
2025-10-07
Recruiting
A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria
NCT07181369Healthy Subjects, Cold Urticaria, Symptomatic Dermographism, Chronic Inducible Urticaria
Granular Therapeutics Limited
Phase 1
72
Berlin, Halle, Marburg, Münster
2025-10-06
Recruiting
Janssen Research & Development, LLC
Phase 2/3
1,092
Berlin, Dachau, Erlangen, Halle, Hanover, Jerichow, Kiel, Leipzig
2025-10-03
Recruiting
Pfizer
Phase 2/3
982
München, Düsseldorf, Dresden, Leipzig, Berlin
2025-10-03
Recruiting
Novo Nordisk A/S
Phase 3
1,280
Bad Oeynhausen, Berlin, Cologne, Dresden, Frankfurt am Main, Freiburg im Breisgau, Jena, Kiel
2025-10-02
Recruiting
Casper Rokx
Not applicable
5,200
Berlin, Cologne, München
2025-10-01
Active, closed
Charite University, Berlin, Germany
Observational
25,000
Berlin
2025-10-01
Recruiting
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
NCT05751044Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
DrugsDasatinib·Cytarabine·Venetoclax·Dexamethasone
Princess Maxima Center for Pediatric Oncology
Phase 1/2
26
Augsburg, Berlin, Essen, Frankfurt, Münster
2025-10-01
Active, closed
Janssen Research & Development, LLC
Phase 3
896
Aachen, Berlin, Dachau, Erlangen, Halle, Hanover, Jerichow, Kiel
2025-10-01
Recruiting
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
NCT05745714Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
DrugsRuxolitinib·Cytarabine·Venetoclax·Dexamethasone
Princess Maxima Center for Pediatric Oncology
Phase 1/2
26
Augsburg, Berlin, Essen, Frankfurt, Münster
2025-10-01
Not yet open
Medical University Innsbruck
Not applicable
80
Berlin, Freiburg im Breisgau, Göttingen, München, Münster, Tübingen
2025-09-30
Active, closed
Neurocrine Switzerland GmbH
Phase 2
7
Berlin, Düsseldorf, Heidelberg
2025-09-30
Recruiting
German Cancer Research Center
Observational
946
Augsburg, Berlin, Cologne, Dresden, Erlangen, Essen, Freiburg im Breisgau, Hamburg
2025-09-29
Recruiting
Pfizer
Phase 3
1,000
Heidelberg, Nürtingen, Ulm, Göttingen, Mettmann, Lübeck, Berlin, Düsseldorf
2025-09-28
Recruiting
Sanofi
Phase 3
124
Berlin, Erlangen, Hanover, Minden, Ulm
2025-09-26
Active, closed
Merck Sharp & Dohme LLC
Phase 2
315
Munich, Cottbus, Herne, Ratingen, Berlin, Hamburg
2025-09-26
Recruiting
Mirum Pharmaceuticals, Inc.
Phase 4
230
Berlin, Essen, Hamburg
2025-09-25
Recruiting
Charite University, Berlin, Germany
Observational
40
Berlin
2025-09-22
Recruiting
Sanofi
Phase 4
218
Berlin, Mainz
2025-09-22
Recruiting
Abiomed Inc.
Observational
200
Heidelberg, Düsseldorf, Dresden, Leipzig, Berlin, Cologne, Essen
2025-09-21
Recruiting
Sanofi
Phase 3
942
Bamberg, Berlin, Bonn, Landsberg am Lech, Peine, Witten
2025-09-17
Recruiting
Sanofi
Phase 3
942
Ahrensburg, Augsburg, Bendorf, Berlin, Darmstadt, Frankfurt, Frankfurt am Main, Hamburg
2025-09-16
Recruiting
Tezspire Cardiac Events PASS
NCT06951867Cardiovascular Events, MACE
DrugTezepelumab
AstraZeneca
Observational
16,640
Berlin
2025-09-15
Active, closed
A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
DrugNerandomilast
Boehringer Ingelheim
Phase 3
414
Berlin, Bonn, Braunschweig, Bremen, Cologne, Düsseldorf, Essen, Freiburg im Breisgau
2025-09-13
Recruiting
Determination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR
NCT07185100Heart Failure With Preserved Ejection Fraction (HFPEF), Renal Dysfunction, Stage B Heart Failure
German Heart Institute
Observational
600
Berlin
2025-09-13
Recruiting
VITAL: Vaccination, Immunity, Time-restricted Eating, Aging and Lifestyle
NCT07000708Vaccination, Immunosenescence, Metabolism
Charite University, Berlin, Germany
Not applicable
24
Berlin
2025-09-10
Recruiting
Hoffmann-La Roche
Phase 2
120
Berlin, Dresden, Essen, Heidelberg, Marburg, Paderborn, Schwerin
2025-09-09
Recruiting
Intuitive Surgical
Observational
1,200
Berlin, Hemer, Wiesbaden
2025-09-09
Recruiting
Charite University, Berlin, Germany
Not applicable
120
Berlin
2025-09-08
Recruiting
Insight Molecular Diagnostics
Observational
125
Heidelberg, Berlin
2025-09-08
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
DrugsCasdatifan·Cabozantinib
Arcus Biosciences, Inc.
Phase 3
720
Berlin, Dresden, Essen, Frankfurt, Freiburg im Breisgau, Halle, Hanover, Heidelberg
2025-09-08
Recruiting
Alnylam Pharmaceuticals
Phase 3
11,000
Aachen, Ahaus, Altenburg, Bad Homburg, Berlin, Brandenburg an der Havel, Bremen, Cologne
2025-09-06
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
125
Düsseldorf, Kiel, Berlin, Dresden, Hamburg
2025-09-04
By invitation
Seaport Therapeutics
Phase 2
360
Berlin, Schwerin, Bad Homburg, Chemnitz
2025-09-02
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Aachen, Bad Homburg, Berlin, Dresden, Essen, Frankfurt, Freiburg im Breisgau, Greifswald
2025-09-02
Recruiting
Charite University, Berlin, Germany
Not applicable
150
Berlin
2025-09
Recruiting
Bial - Portela C S.A.
Observational
90
Berlin, Bochum, Freiburg im Breisgau, Fulda, Hetzdorf, Osnabrück, Siegen, Sundern
2025-08-27
Recruiting
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
DrugsEmpasiprubart·IVIG
argenx
Phase 3
218
Berlin, Kiel
2025-08-22
Active, closed
Merz Therapeutics GmbH
Phase 3
808
Berlin, Frankfurt, Greifswald, Kassel, Kiel
2025-08-21
Active, closed
Merz Therapeutics GmbH
Phase 3
997
Berlin, Frankfurt, Greifswald, Kassel, Kiel
2025-08-21
Recruiting
Sanofi
Phase 3
90
Berlin, Essen, Frankfurt, Leipzig
2025-08-18
Recruiting
A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany
NCT07102368Inflammatory Bowel Disease, Colitis, Ulcerative, Crohn's Disease
Janssen-Cilag G.m.b.H
Observational
500
Berlin
2025-08-18
Recruiting
Novo Nordisk A/S
Phase 4
586
Amberg, Bad Mergentheim, Bad Reichenhall, Berlin, Bünde, Daaden, Dortmund, Dresden
2025-08-15
Recruiting
Technical University of Munich
Not applicable
322
Munich, Frankfurt am Main, Berlin, Aachen, Cologne, Dresden, Essen, Göttingen
2025-08-13
Recruiting
Sanofi
Phase 3
192
Berlin, Essen, Stuttgart
2025-08-12
Recruiting
BioNTech SE
Phase 1/2
1,438
Berlin, Essen, Mainz, München, Tübingen
2025-08-12
Recruiting
Galderma R&D
Observational
600
Karlsruhe, Erlangen, Rostock, Kiel, Ahaus, Berlin, Bielefeld, Haslach
2025-08-11
Recruiting
Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study
NCT07264426Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
DrugEfgartigimod PH20
argenx
Observational
200
Berlin, Bochum, Cologne, Düsseldorf, Frankfurt, Giessen, Göttingen, Hamburg
2025-08-11
Active, closed
Novo Nordisk A/S
Phase 3
877
Bad Mergentheim, Bad Oeynhausen, Berlin, Bochum, Dresden, Eisenach, Essen, Gelnhausen
2025-08-11
Recruiting
Charite University, Berlin, Germany
Observational
50
Berlin
2025-08-07
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Berlin, München
2025-08-07
Active, closed
AstraZeneca
Phase 3
212
Berlin, Düsseldorf, Kaiserslautern, München, Würzburg
2025-08-07
Recruiting
AstraZeneca
Phase 3
700
Augsburg, Berlin, Braunschweig, Cologne, Dresden, Duisburg, Düsseldorf, Essen
2025-08-06
Recruiting
Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy
NCT06113237Maternal Complications, Pregnancy Complication, Birth Outcomes, Adverse, Pregnancy
DrugCannabidiol
Jazz Pharmaceuticals
Observational
50
Berlin
2025-08-05
Recruiting
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
227
Berlin, Bochum, Bonn, Braunschweig, Bremen, Darmstadt, Flensburg, Freiburg im Breisgau
2025-08-05
Recruiting
Pfizer
Phase 3
400
Ravensburg, Ulm, Augsburg, Erlangen, Essen, Magdeburg, Berlin, Hamburg
2025-08-05
Recruiting
Charite University, Berlin, Germany
Not applicable
60
Berlin
2025-08-01
Recruiting
dsm-firmenich Switzerland AG
Not applicable
236
Berlin
2025-08-01
Active, closed
Vir Biotechnology, Inc.
Phase 3
150
Berlin, Essen, Frankfurt am Main, Hanover
2025-07-30
Active, closed
Boston Scientific Corporation
Observational
550
Berlin, Frankfurt, Hamburg
2025-07-30
Recruiting
Harmony TPV EMEA PMS
NCT06906926Severe Pulmonary Valve Regurgitation
Medtronic Cardiovascular
Not applicable
80
Bad Oeynhausen, Berlin, Leipzig, Munich
2025-07-30
Active, closed
Amgen
Phase 3
12,800
Bad Homburg, Bad Krozingen, Bad Oeynhausen, Berlin, Bochum, Bonn, Detmold, Dortmund
2025-07-25
Recruiting
Pharmazz, Inc.
Phase 3
514
Altenburg, Göttingen, Rhein, Minden, Recklinghausen, Berlin, Bad Neustadt an der Saale, Erlangen
2025-07-24
Recruiting
Windward Bio
Phase 2
600
Berlin, München, Bendorf, Lübeck, Darmstadt, Frankfurt am Main, Leipzig, Mainz
2025-07-24
Recruiting
Boehringer Ingelheim
Phase 3
11,800
Bad Homburg, Bad Krozingen, Bad Oeynhausen, Berlin, Bochum, Bremen, Bruchsal, Coburg
2025-07-22
Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
DrugsZanzalintinib·Everolimus
Exelixis
Phase 2/3
440
Berlin, Erlangen, Essen, Mainz, Marburg, Tübingen, Würzburg
2025-07-21
Recruiting
CSL Behring
Observational
200
Ulm, Frankfurt am Main, Hanover, Leipzig, Hamburg, Berlin
2025-07-21
Recruiting
Grupo Español Multidisciplinar de Melanoma
Phase 2
19
Berlin
2025-07-18
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
NCT07093463Microbiome Dysbiosis, Gut Health
dsm-firmenich Switzerland AG
Not applicable
90
Berlin
2025-07-18
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
Berlin, Esslingen am Neckar, Großhansdorf, Immenhausen, Velbert
2025-07-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
477
Essen, Berlin, Hamburg
2025-07-16
Recruiting
University Hospital, Basel, Switzerland
Phase 2
150
Berlin, Würzburg
2025-07-15
Active, closed
Bluefin Biomedicine, Inc.
Phase 2
225
Bad Bentheim, Berlin, Göttingen, Heidelberg, Münster
2025-07-15
Recruiting
Galderma R&D
Observational
1,000
Karlsruhe, Langenau, Augsburg, Erlangen, Regensburg, Remscheid, Ahaus, Berlin
2025-07-14
Recruiting
Bristol-Myers Squibb
Phase 3
586
Mannheim, Münster, Mainz, Berlin, Aachen, Bremen, Hamburg, Munich
2025-07-14
Active, closed
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
89
Leipzig, Magdeburg, Berlin, Cologne, Erlangen, Herne
2025-07-14
Recruiting
4TEEN4 Pharmaceuticals GmbH
Phase 1/2
90
Berlin, Freiburg im Breisgau, Hamburg, Leipzig, Mannheim
2025-07-13
Recruiting
ARS Pharmaceuticals, Inc.
Phase 2
42
Berlin
2025-07-09
Active, closed
Xenon Pharmaceuticals Inc.
Phase 3
450
Berlin, Rosenheim
2025-07-08
Recruiting
neurescue
Not applicable
84
Berlin, Heidelberg
2025-07-07
Recruiting
Anocca AB
Phase 1/2
96
Berlin, Dresden, Heidelberg, Leipzig, München, Tübingen
2025-07-03
Recruiting
Alnylam Pharmaceuticals
Phase 3
1,750
Berlin, Cologne, Dresden, Göttingen, Hanover, Heidelberg, Leipzig, Magdeburg
2025-07-02
Recruiting
Charite University, Berlin, Germany
Observational
2,500
Bamberg, Berlin, Essen
2025-07-01
Recruiting
Sanofi
Observational
350
Auerbach, Augsburg, Bad Homburg, Berlin, Burgwedel, Darmstadt, Erkelenz, Flensburg
2025-07-01
Recruiting
Preoperative Fasting and the Gut Microbiome Before Hip Replacement
NCT07651462Hip Osteoarthritis, Arthroplasty, Replacement, Hip, Postoperative Complications, Surgical Wound Infection
Charite University, Berlin, Germany
Not applicable
130
Berlin
2025-07-01
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Adriamycin·Xeloda·Paraplatin
Merck Sharp & Dohme LLC
Phase 3
2,400
Erlangen, Munich, Paderborn, Koblenz, Saarbrücken, Berlin
2025-06-30
Active, closed
Pfizer
Phase 1/2
74
Essen, Dresden, Berlin, Leipzig
2025-06-30
Recruiting
Novo Nordisk A/S
Phase 2
200
Berlin, Dresden, Essen, Frankfurt am Main, Halle, Hanover, Heidelberg, Kiel
2025-06-30
Active, closed
Mundipharma Research Limited
Phase 2
60
Berlin, Cologne, Gauting
2025-06-30
Recruiting
AstraZeneca
Phase 2
987
Ahrensburg, Bendorf, Berlin, Darmstadt, Halle, Hanover, Landsberg, Leipzig
2025-06-27
By invitation
MoonLake Immunotherapeutics AG
Phase 3
835
Halle, Augsburg, Bad Bentheim, Berlin, Bielefeld, Bochum, Bramsche, Darmstadt
2025-06-27
Recruiting
Novo Nordisk A/S
Phase 2
200
Berlin, Dresden, Essen, Frankfurt am Main, Halle, Hanover, Heidelberg, Kiel
2025-06-27
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
5,056
Bad Berka, Bad Neustadt an der Saale, Bad Segeberg, Berlin, Bonn, Detmold, Dortmund, Dresden
2025-06-25
Recruiting
IP-coated Revision Hip Implants
NCT06737809Peri-Prosthetic Joint Infection
Aesculap AG
Not applicable
268
Berlin
2025-06-25
Recruiting
Novartis Pharmaceuticals
Phase 3
400
Marburg, Berlin, Bochum, Erbach im Odenwald, Essen, Greifswald, Heidelberg, Münster
2025-06-23
Active, closed
Incyte Corporation
Phase 3
580
Berlin, Bochum, Darmstadt, Dresden, Erlangen, Hamburg, Lübeck
2025-06-23
Recruiting
Aesculap AG
Not applicable
76
Aachen, Berlin, Freiburg im Breisgau
2025-06-20
Active, closed
Novartis Pharmaceuticals
Phase 1/2
27
Freiburg im Breisgau, Göttingen, Cologne, Berlin, Ulm
2025-06-20
Recruiting
GlaxoSmithKline
Phase 3
981
Löwenstein, Donaustauf, Peine, Essen, Ahrensburg, Berlin, Bonn, Frankfurt am Main
2025-06-20
Recruiting
Seaport Therapeutics
Phase 2
360
Berlin, Schwerin, Bad Homburg, Chemnitz
2025-06-19
Active, closed
Arrowhead Pharmaceuticals
Phase 3
70
Berlin
2025-06-17
Recruiting
BeOne Medicines
Phase 3
630
Berlin, Cologne, Dresden, Jena, Kiel, Mutlangen, München, Neubrandenburg
2025-06-11
Recruiting
BioNTech SE
Phase 3
480
Berlin, Essen, Kassel, München, Tübingen
2025-06-10
Active, closed
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
NCT07000136Heterozygous Familial Hypercholesterolaemia
DrugAZD0780
AstraZeneca
Phase 3
473
Berlin, Dresden, Leipzig
2025-06-10
Recruiting
Calico Life Sciences LLC
Phase 2
240
Heidelberg, Munich, Hanover, Cologne, Berlin
2025-06-09
Recruiting
Boehringer Ingelheim
Phase 3
1,755
Aachen, Ahrensburg, Bamberg, Berlin, Bochum, Bonn, Cologne, Donaustauf
2025-06-09
Active, closed
Merck Sharp & Dohme LLC
Phase 2
149
Frankfurt am Main, Berlin
2025-06-09
Recruiting
AstraZeneca
Phase 3
15,100
Amberg, Bad Bevensen, Bad Friedrichshall, Bad Homburg, Bad Oeynhausen, Bechhofen, Berlin, Bielefeld
2025-06-04
Active, closed
Incyte Corporation
Phase 3
9
Aachen, Berlin, Cologne, Dresden, Erlangen, Frankfurt am Main, Freiburg im Breisgau, Göttingen
2025-06-04
Active, closed
Stoke Therapeutics, Inc
Phase 3
170
Berlin, Bonn, Frankfurt, Friedberg, Heidelberg, München
2025-06-04
Recruiting
Charite University, Berlin, Germany
Not applicable
186
Hamburg, Aachen, Bonn, Münster, Berlin, Hanover, München, Regensburg
2025-06-02
Recruiting
MediWound Ltd
Phase 3
216
München, Chemnitz, Berlin, Bochum, Dresden, Erlangen, Kiel
2025-06-01
Recruiting
Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC)
NCT06904872Short Bowel Syndrome, Malabsorption Syndromes, Short Gut Syndrome, Post-Op Complication
DrugCrofelemer
Napo Therapeutics, S.p.A.
Phase 2
18
Aachen, Berlin, Essen, Hamburg, Rostock
2025-05-29
Active, closed
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
NCT06931405Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Blueprint Medicines Corporation
Phase 2
105
Berlin, Dresden, Frankfurt am Main, Hanover, Mainz, Tübingen
2025-05-28
Active, closed
AstraZeneca
Phase 3
3,103
Amberg, Bad Homburg, Berlin, Dresden, Essen, Falkensee, Frankfurt, Freiburg im Breisgau
2025-05-28
Recruiting
Merck Sharp & Dohme LLC
Phase 2
144
Tübingen, Berlin
2025-05-28
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
Berlin, Brandenburg an der Havel, Dachau, Frankfurt am Main, Kiel, Leipzig, Munich, Ulm
2025-05-27
Recruiting
Chiesi Farmaceutici S.p.A.
Observational
10
Berlin
2025-05-23
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
500
Berlin, Essen, Frankfurt am Main, Hanover, Leipzig, Mainz, Munich, Nuremberg
2025-05-22
Recruiting
Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria
NCT06865651Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 2
44
Dresden, Berlin, Mainz, Tübingen
2025-05-22
Active, closed
Swedish Orphan Biovitrum
Phase 4
252
Berlin, Bonn, Frankfurt am Main, Hamburg, Munich
2025-05-21
Active, closed
Upstream Bio Inc.
Phase 2
396
Hamburg, Berlin, Hessen, Leipzig, Bendorf, Mainz
2025-05-21
Recruiting
AstraZeneca
Observational
150
Amberg, Bad Nauheim, Bautzen, Berlin, Bielefeld, Bonn, Borna, Bottrop
2025-05-20
Recruiting
Boehringer Ingelheim
Phase 3
4,200
Bad Friedrichshall, Bad Homburg, Bamberg, Berlin, Bonn, Bünde, Coburg, Dresden
2025-05-20
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 3
450
Berlin, Erlangen, Lübeck, Mainz Am Rhein, Münster
2025-05-19
Recruiting
Prof. Dr. Dr. Birgit Burkhardt
Phase 1
18
Göttingen, Greifswald, Essen, Mainz, Berlin
2025-05-16
Recruiting
Clinical Trial to Investigate the Safety and Efficacy of Two Dexamfetamine Sulfate Formulations in Adults With ADHD and Moderate to Severe Depression
NCT06967857Attention-Deficit/Hyperactivity Disorder (ADHD), Depression - Major Depressive Disorder
Prof. Dr. Frank Behrens
Phase 2
105
Berlin, Bonn, Frankfurt, Leipzig, München
2025-05-15
Recruiting
Project VERANDA: Requirement Analysis Survey
NCT07424872Observational Study
Berlin Institute of Health @ Charité
Observational
100
Berlin
2025-05-13
Active, closed
Merck Sharp & Dohme LLC
Phase 2
96
Tübingen, Berlin
2025-05-13
Recruiting
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies
DrugAcoramidis
Eidos Therapeutics, a BridgeBio company
Phase 3
587
Berlin, Heidelberg, Mainz
2025-05-12
Recruiting
Joseph Broderick, MD
Phase 3
350
Heidelberg, Erlangen, Frankfurt am Main, Augsburg, Berlin, Hamburg, Tübingen
2025-05-06
Recruiting
Takeda
Phase 3
225
Bonn, Düsseldorf, Leipzig, Halle, Magdeburg, Berlin
2025-05-06
Recruiting
AstraZeneca
Phase 3
1,220
Aachen, Berlin, Bonn, Chemnitz, Cologne, Dortmund, Dresden, Erlangen
2025-05-06
Recruiting
Takeda
Phase 3
59
Mannheim, Ulm, Marburg, Hanover, Berlin
2025-05-06
Recruiting
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3
448
Berlin, Bochum, Bonn, Braunschweig, Bremen, Darmstadt, Essen, Flensburg
2025-05-05
Active, closed
Novartis Pharmaceuticals
Phase 3
246
Stuttgart, Potsdam, Chemnitz, Leipzig, Berlin, Bielefeld, Gelnhausen, Mannheim
2025-04-30
Active, closed
Eli Lilly and Company
Phase 3
487
Bad Homburg, Berlin, Cologne, Dresden, Essen, Leipzig, Oldenburg
2025-04-30
Active, closed
Eli Lilly and Company
Phase 3
487
Bad Homburg, Berlin, Cologne, Dresden, Essen, Leipzig, Oldenburg
2025-04-30
Active, closed
Eli Lilly and Company
Phase 3
974
Bad Homburg, Berlin, Cologne, Dresden, Essen, Leipzig, Oldenburg
2025-04-30
Recruiting
Takeda
Observational
30
Rüdersdorf, Marburg, Bochum, Berlin
2025-04-29
Recruiting
Center for Epidemiology and Health Research, Germany
Observational
68,100
Berlin
2025-04-24
Recruiting
Malek Bajbouj
Not applicable
100
Berlin
2025-04-22
Recruiting
Vanda Pharmaceuticals
Phase 3
420
Berlin, Leipzig
2025-04-21
Recruiting
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
NCT06951217Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc.
Phase 2
340
Hanover, Berlin, Frankfurt
2025-04-17
Active, closed
Merck Sharp & Dohme LLC
Phase 2
440
Heidelberg, München, Giessen, Cologne, Mainz, Dresden, Berlin
2025-04-16
Active, closed
Janssen Research & Development, LLC
Phase 3
752
Augsburg, Bad Bentheim, Berlin, Bonn, Bramsche, Darmstadt, Dresden, Friedrichshafen
2025-04-15
Recruiting
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
NCT06906341Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
DrugsNab-paclitaxel /m^2·Relacorilant·Bevacizumab
Corcept Therapeutics
Phase 2
270
Aachen, Berlin, Kempten
2025-04-11
Recruiting
Société des Produits Nestlé (SPN)
Not applicable
400
Berlin, Düsseldorf, Frankfurt, Spandau, Wesel
2025-04-10
Recruiting
A Clinical Study of Arfolitixorin in Patients With mCRC
NCT06922383Metastatic Colorectal Cancer (mCRC)
Isofol Medical AB
Phase 1/2
90
Berlin, Essen, München
2025-04-10
Recruiting
BeOne Medicines
Phase 3
250
Augsburg, Berlin, Chemnitz, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg
2025-04-10
Recruiting
AstraZeneca
Phase 3
830
Amberg, Augsburg, by, Bad Saarow, Berlin, Bonn, Braunschweig, Essen, Flensburg
2025-04-10
Active, closed
Arrowhead Pharmaceuticals
Phase 3
710
Magdeburg, Berlin, Deggingen
2025-04-09
Active, closed
UCB Biopharma SRL
Phase 3
43
Berlin
2025-04-07
Active, closed
Charite University, Berlin, Germany
Not applicable
30
Berlin
2025-04-04
Recruiting
Gilead Sciences
Phase 3
695
Berlin, Bochum, Chemnitz, Esslingen am Neckar, Hamburg, Löwenstein, Minden, Munich
2025-04-04
Active, closed
Philip Morris Products S.A.
Not applicable
290
Berlin, Delitzsch, Hanover, Karlsruhe, Leipzig, Neu-Isenburg, Offenbach, Reinfeld
2025-04-02
Not yet open
Buda Health Center
Observational
300
Berlin
2025-04-01
Recruiting
Troubled-Desire & Therapeutic Chat for Reduction of CSAM Use (TD-CHAT)
NCT06852443Prevention, Well Being, Sexual Behavior, Behavior Change
Charite University, Berlin, Germany
Not applicable
180
Berlin
2025-04-01
Not yet open
Pre-Operative Treatment in REseCTable COlon CanceR
NCT06899477Colo-rectal Cancer, Colon Cancer, Colon Carcinoma
DrugsMFOLFOXIRI·MFOLFOX6·Folfox·Irinotecan
Dominik Paul Modest
Phase 3
714
Berlin, Berlin-Spandau, Chemnitz, Cologne, Dessau, Dortmund, Frankfurt, Hamburg
2025-04
Recruiting
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Observational
683
Berlin, Marburg
2025-03-31
Recruiting
Universität Münster
Phase 3
1,022
Berlin, Bonn, Mainz, Münster
2025-03-31
Recruiting
AstraZeneca
Phase 3
600
Berlin, Chemnitz, Dessau, Dresden, Düsseldorf, Essen, Hamburg, Kassel
2025-03-27
Recruiting
Daiichi Sankyo
Phase 3
510
Berlin, Bonn, Dresden, Frankfurt am Main, Hamburg, Jena, Leipzig, Nuremberg
2025-03-27
Recruiting
Eli Lilly and Company
Phase 3
700
Berlin, Chemnitz, Cologne, Erfurt, Gauting, Georgsmarienhütte, Großhansdorf, Halle
2025-03-27
Active, closed
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 1/2
36
Berlin, Chemnitz, Essen, Frankfurt am Main, Halle, Hamburg, Heidelberg, Jena
2025-03-25
Active, closed
Immutep S.A.S.
Phase 3
756
Amberg, Augsburg, Bad Saarow, Berlin, Cologne, Frankfurt, Frankfurt am Main, Gauting
2025-03-21
Active, closed
Astria Therapeutics, Inc.
Phase 3
157
Berlin, Frankfurt, Hanover
2025-03-20
Active, closed
Novartis Pharmaceuticals
Phase 3
565
Freiburg im Breisgau, Würzburg, Frankfurt am Main, Düsseldorf, Merzig, Leipzig, Bad Bentheim, Berlin
2025-03-20
Recruiting
Daiichi Sankyo
Phase 3
582
Berlin, Bonn, Detmold, Hamburg, Heilbronn, Jena, Mannheim, Marburg
2025-03-19
Recruiting
AstraZeneca
Phase 3
990
Bendorf, Berlin, Haltern am See, Hanover, Immenhausen, Lübeck, Marburg, Rosenheim
2025-03-18
Recruiting
Immunovant Sciences GmbH
Phase 2
162
Berlin, Bochum, Essen, Tübingen, Ulm, Würzburg
2025-03-18
Recruiting
Hoffmann-La Roche
Phase 3
600
Berlin, Frankfurt, Halle, Hanover, Jena, Mannheim, Ulm
2025-03-17
Active, closed
Amgen
Phase 3
1,105
Aachen, Bad Krozingen, Bad Mergentheim, Bad Oeynhausen, Berlin, Elsterwerda, Essen, Falkensee
2025-03-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Erlangen, Düsseldorf, Essen, Saarbrücken, Leipzig, Berlin
2025-03-16
Recruiting
AstraZeneca
Phase 3
11,300
Aachen, Amberg, Bad Homburg, Bad Oeynhausen, Bamberg, Bechhofen, Berlin, Bochum
2025-03-14
Rows per page Showing 1–500 of 1591
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 November 2026. https://priyalifescience.com/clinical-trials-germany/city/berlin

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,081 studies in total at the last sync on 13 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,591 of those studies with a site in Berlin.

How many clinical trials are recruiting in Berlin?

827 of the 1,591 studies on this page are recruiting new participants as of the 13 Nov 2026, 03:18 UTC sync. A further 55 have not yet opened recruitment, 677 are active but closed to new participants, and 32 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Berlin), 1,591 studies
PhaseStudiesRecruitingShare
Phase 366829942%
Observational28319117.8%
Phase 226612116.7%
Not applicable1769511.1%
Phase 162333.9%
Phase 1/255373.5%
Phase 2/344272.8%
Phase 436232.3%
Early Phase 1110.1%

Most active sponsors

Lead sponsors with the most studies (Berlin)
Lead sponsorStudiesRecruiting
AstraZeneca11870
Charite University, Berlin, Germany8970
Janssen Research & Development, LLC4915
Eli Lilly and Company4725
Novartis Pharmaceuticals4518
Hoffmann-La Roche4012
Merck Sharp & Dohme LLC4017
Sanofi3217
Boehringer Ingelheim2819
Pfizer2814
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.